Albumin Market
Report ID: SQMIG15N2001
Report ID: SQMIG15N2001
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG15N2001 |
Region:
Global |
Published Date: February, 2025
Pages:
188
|Tables:
88
|Figures:
71
Albumin Market size was valued at USD 7.08 Billion in 2024 and is poised to grow from USD 7.5 Billion in 2025 to USD 11.87 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026–2033).
Critical applications of albumin protein in the medical field such as increasing blood volume, liver diseases, and burns treatment will lead to steady growth in the industry. Crucial functions of albumin are maintaining osmotic pressure, transporting substances, and supporting different therapeutic uses. Based on the global albumin market analysis, companies focusing on innovation, efficacy, and sustainability have significant opportunities.
The global albumin market is growing drastically mainly because of the increasing occurrence of life-threatening diseases, individual liver diseases, infections, and cardiac surgeries. Besides this, there is a huge introduction of new products by many leading industry firms that drives this growth enormously. The growth in the number of surgeries across the globe is one of the most important sources of consumption of albumin. The National Library of Medicine estimated that, in 2022, major surgeries totaling 310 million took place; this would imply around 40 to 50 million cases within the United States, with nearly 20 million being within Europe.
Other drivers for the global albumin market growth include increased demand in research and development, a rise in non-therapeutic use of albumin, and a rise in immunoglobulins and plasma collection. Such nanoparticles have been discovered to exhibit great applicability in medicinal fields due to the fact that it has developed significantly in drug delivery systems. Research about it has enhanced the solubility, stability, and circulating time of the drugs encased within the nanoparticles. For instance, for breast cancer, the formulation can be used by Abraxane which is a well-known chemotherapy drug in enhancing the delivery of paclitaxel since it is an excellent anticancer agent. Other significant uses of albumin include crystallography, cell culture, diagnostic assays, and stabilization of enzymes and biomolecules. The demand for the Albumin market will be influenced by government regulations and guidelines. There will be guidelines issued by regulatory agencies to ensure safe manufacture, rigorous testing, and smooth distribution of commodities. These standards also help raise consumer confidence.
Grifols SA was able to finish the recruitment of participants for its Phase III PRECIOSA clinical study in July 2023. This clinical study evaluates the long-term efficacy of Albutein (albumin-human injectable) treatment in patients with decompensated cirrhosis. This is important because it would be known whether prolonging albumin therapy could increase survival rates, thus improving patient outcomes. With decompensated cirrhosis representing a very serious stage of the disease with an extremely high mortality rate, this study's results may open doors to a totally new approach toward the management of cirrhosis and prolongation of patient life.
Shilpa Biologicals, which is the wholly owned subsidiary of Shilpa Medicare, claimed to file the first DMF with USFDA for the novel recombinant Human Albumin 20%, in June 2024. It had been developed with the patented and environmental-friendly process with a feature to ensure excellent consistency and ensure cost competitiveness at scale manufacturing capability. Shilpa Biologicals is well positioned to transform the albumin manufacturing market by tapping into advanced biotechnology advancements that are greener, cheaper, and more commercialized replacement for plasma-derived albumin.
Albumedix Ltd. stated that during the June 2023 quarterly update, it was expanding its strategic collaboration with Valneva SE, one of the world's leading companies working on the development of vaccines to address key, unmet medical needs in preventing infectious diseases. This was after the UK's Medicines & Healthcare products Regulatory Agency had approved the inactivated Covid-19 vaccine from Valneva. The two companies are now looking to further enhance the stability and efficacy of the vaccines through proprietary albumin-based formulations from Albumedix. Both combine their expertise to help advance innovative solutions that strengthen global immunization efforts and improve access to life-saving vaccines around the world.
Market snapshot - 2026-2033
Global Market Size
USD 6.69 billion
Largest Segment
Human Serum
Fastest Growth
Recombinant
Growth Rate
5.9% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Albumin Market is segmented by Type, Application, Sales Channel, End-User and region. Based on Type, the market is segmented into Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin. Based on Application, the market is segmented into Therapeutics, Drug Formulation and Vaccines, Component of Media and Other Applications. Based on Sales Channel, the market is segmented into Business-To-Consumer (B2C) and Business-To-Business (B2B). Based on End-User, the market is segmented into Hospitals and Clinics, Pharmaceutical and Biotechnology Companies and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Analysis by Product
As per the 2024 global albumin market forecast, the largest market share is held by the human serum segment, since it has so many therapeutic applications. It was used in burn cases, traumatic cases, and hypoalbuminemia. This product is in high demand from pharmaceuticals, therapeutics, and research. The high demand for the product is seen in pharmaceuticals, therapeutics, and research. Moreover, the capacity of this product to maintain critical blood volume and pressure enhances its appeal in the market. The Chest Journal has made recommendations on the use of albumin in adult critical care, with three recommendations, pediatric critical care, with one recommendation, neonatal critical care, with two recommendations, and cardiovascular surgery, with two recommendations. This forecast for the albumin market puts into perspective the critical role of human serum albumin in modern medical practices.
Through regulatory benefits, scalability, and safety compared to HSA and BSA, the recombinant category will be expected to show severe advantages in the years ahead. In the wake of biotechnology production, recombinant albumin is free from all possibilities of viral contamination, prion contamination, or contamination by pathogen from plasma-derived albumin. These recombinant proteins are gaining favor from the USFDA and EMA due to reduced immunogenicity and consistent quality. It is also significantly more environmentally friendly, cheaper, and scalable than conventional extraction of albumin. Recombinant albumin is much sought after today in the fields of application in regenerative medicine, formulation of vaccines, cell culture media, and drug delivery.
Analysis By Application
The therapeutics category was the largest market share in 2024. This is due to its large use in treating a variety of medical diseases, including liver diseases, hypovolemia, shock, burns, and complications from surgery. Applications that include use as a drug-delivery or therapeutically to maintain blood volume and pressure are an absolute necessity in clinical practice. The albumin is the latest versatile drug carrier used in the therapeutic and diagnostic agents used in diagnosing and treating diabetes, cancer, rheumatoid arthritis, and infectious diseases. The market continues to grow since many people get chronic illnesses, making therapeutics continue to dominate the main applications of albumin.
The drug formulation segment is expected to witness maximum market share during the forecasted period because of extensive usage in the stabilization of therapeutic medications, vaccines, and biologics. Albumin is one of the widely used excipients to enhance bioavailability, shelf life, and solubility of drugs. Albumin is commonly used as an excipient for enhanced bioavailability, extended shelf life, and drug solubility. Human serum albumin and recombinant albumin play a vital role in drug delivery systems by offering stability and avoiding aggregation of the drug. Increased demand for albumin in pharmaceutical formulations is mainly because of the rising demand for gene therapies, biosimilars, and monoclonal antibodies. The segment is further supported by regulatory approvals and developments in albumin-based drug carriers. In the future, drug formulation is predicted to continue dominating the global albumin industry since more investments will be channeled into research and development.
To get detailed segments analysis, Request a Free Sample Report
North America currently leads the markets globally, where the biopharmaceutical industries are strong in terms of capital investment and with significant research investments. Advanced medical infrastructure in that region also attracts a high quantity of demand from the albumin market. Moreover, the diseases that are prevailing in this particular region, that is, more chronic diseases among the population with liver disorders and cancer, raise the demand to a greater level. Albumin is a drug carrier that is often used in the field of nanomedicine owing to its characteristic properties such as being non-toxic, biodegradable, non-immunogenic, and highly abundant in plasma. In addition, North America remains ahead in the race primarily due to the infinite developments in biotechnology. Furthermore, favorable reimbursement policies and strong governmental support also boost the growth in the market.
The US dominated the biopharmaceutical innovation and high-end healthcare technologies market share of the global albumin market in 2024. This is since the country has been at the vanguard of the evolution of regenerative medicine and the formulation of albumin-based medications since its inception, due to the presence of prominent research foundations and pharmaceutical companies. The market has also been stimulated by the heightened utilization of albumin in cell therapies, vaccine stabilization, and drug delivery systems.
Asia-Pacific is expected to dominate the albumin market due to the high demand from China, the world's largest producer and consumer of human serum albumin (HSA). The albumin market is, at present, driven by the rapid expansion of the biotechnology industry, an increase in the number of plasma collection centers, and increased investments in healthcare. The regional domination is further driven by the surging utilization of protein in drug formulation, diagnostics, and regenerative medicine, and the expanding pharmaceutical sector. The vast application of albumin in treatments of liver disease, surgery, and drug delivery applications is the major factor that leads to a higher demand for albumin in China.
Europe has taken a large market share in the albumin market due to the rising demand for albumin in regenerative medicine and formulation of drugs and its strong biotechnology industries and developments in regulations. The use of recombinant albumin has increased due to the implementation of strict regulations that ensure the production of high-quality albumin by the European Medicines Agency, EMA. Germany, the United Kingdom, and France are the major contributors to the demand for albumin, especially in the context of biopharmaceuticals and drug delivery systems. The growing incidence of chronic diseases, such as liver and renal disorders, has further accelerated the use of albumin in medical therapies.
The albumin market is growing in Latin America due to the growing availability of treatments based on albumin, expanded plasma collection operations, and more investments in health care. Key countries in this region are being led by the countries of Brazil, Mexico, and Argentina because of government initiatives to promote progress in biopharmaceutical sectors and enhance infrastructure for health care. The demand for albumin is particularly higher in applications such as vaccine stabilization, critical care treatments, and drug formulation. However, the region has been facing issues such as domestic production facilities that are not large enough, delayed regulatory approvals, and dependence on imports, which have slowed the growth of the market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Albumin Market Drivers
Increasing Demand for Albumin in Drug Formulation and Therapeutics
More Preference to the Recombinant Albumin
Albumin Market Restraints
Supply chain Difficulties and High Production Cost
Ethical and Regulatory Issues of Plasma-Derived Albumin
Request Free Customization of this report to help us to meet your business objectives.
The global albumin market is competitive. With regulatory approvals and strategic partnerships dominating the market, the focus here is on new product innovation, which is necessary to enhance a company's strength in the industry. Companies with plasma-derived production of albumin include Grifols SA, CSL Behring, Takeda Pharmaceutical, Octapharma, and Baxter International. But Shilpa Biologicals, Albumedix, and Merck KGaA are slowly emerging as newcomers in recombinant albumin technologies. The investments in biopharmaceuticals, research and development along with regional expansions exacerbate the competition in the market.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected using Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global albumin market outlook is predicted to undergo tremendous growth, as the demand for drug formulation, vaccine stabilization, and regenerative medicine has driven the expansion of the market. Asia-Pacific is expected to dominate in the next few years mainly because of China's high production and consumption, though it lags due to the leading position held by North America, mostly because of the dominance of the biopharmaceutical industry of that region. The market is currently shifting toward recombinant albumin, which is a scalable and safer alternative to plasma-derived products. However, growth is hindered by high production costs, stringent regulations, and ethical concerns. Due to increased investment in biopharmaceuticals, technological advancements, and ongoing research and development, the albumin market is expected to expand, providing new opportunities for innovation and therapeutic applications on a global scale.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 7.08 Billion |
| Market size value in 2033 | USD 11.87 Billion |
| Growth Rate | 5.9% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Albumin Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Albumin Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Albumin Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Albumin Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
